ArticlePediatric research2025
Association of patent ductus arteriosus duration with bronchopulmonary dysplasia and mortality: a cohort study.
Article in Pediatric research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Case Report: Comprehensive management of bedside ligation of patent ductus arteriosus in an extremely low birth weight infant.Frontiers in cardiovascular medicine · 2026Article
- Cardio-Metabolic Risk in Adults Born Preterm: A Narrative Review.Journal of clinical medicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWe evaluated if the number of days of exposure to a hemodynamically significant patent ductus arteriosus (hsPDA) is associated with bronchopulmonary dysplasia (BPD) and/or mortality in preterm infants.
methodsWe conducted a retrospective cohort study of preterm infants (birth weight ≤ 1500 g or gestational age < 30 weeks), admitted between January 2017 to December 2022. HsPDA was defined using Neonatologist Performed Echocardiography criteria. Logistic regression was used to assess the relationship between the duration of hsPDA and BPD/death. Additional analyses explored non-linear associations using penalized splines and quadratic functions.
resultsWe included 424 neonates: 204 developed BPD/death. The duration of hsPDA was associated to increased risk of BPD/death (OR = 1.67, 95% CI 1.17-2.56, p < 0.001), adjusted for birth weight, 5' APGAR score, IVH, durations of mechanical and non-invasive ventilation. We found a progressive increase in the OR for BPD/death during the first week of exposure, followed by a plateau.
conclusionThe duration of exposure to hsPDA is associated with adverse neonatal outcomes, (BPD/ death). The risk progressively increases during the first week of exposure followed by a plateau. These findings suggest that the first week of exposure may represent a critical window of opportunity. IMPACT: The duration of exposure to a hemodynamically significant PDA is associated with an increased risk of BPD/death. This risk progressively rises during the first week of exposure and then plateaus thereafter. This study explores the association between BPD/death and the duration of exposure to a hemodynamically significant PDA, longitudinally assessed using a comprehensive echocardiographic protocol. The findings suggest the first week of exposure to a hemodynamically significant PDA is a critical window for interventions to impact outcomes. Future research should focus on identifying high-risk population and developing targeted treatments during this pivotal period.
Indexed as
Identifiers
40329082What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.